At the time of writing, UroGen Pharma Ltd [URGN] stock is trading at $19.71, down -1.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The URGN shares have gain 11.07% over the last week, with a monthly amount glided 27.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on June 16, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $50 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on May 22, 2025. On April 16, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $23 on the stock. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on August 22, 2024. Jefferies downgraded its rating to Hold for this stock on February 08, 2023, and downed its price target to $10. In a note dated April 27, 2022, Berenberg initiated an Buy rating and provided a target price of $20 on this stock.
For the past year, the stock price of UroGen Pharma Ltd fluctuated between $3.42 and $21.01. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $19.71 at the most recent close of the market. An investor can expect a potential return of 19.23% based on the average URGN price forecast.
Analyzing the URGN fundamentals
According to UroGen Pharma Ltd [NASDAQ:URGN], the company’s sales were 94.24M for trailing twelve months, which represents an 10.83% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.6%, and Net Profit Margin reading is -1.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.74, Equity is 5.03 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.35 points at the first support level, and at 18.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.24, and for the 2nd resistance point, it is at 20.76.
Ratios To Look Out For
It is important to note that UroGen Pharma Ltd [NASDAQ:URGN] has a current ratio of 4.14. In addition, the Quick Ratio stands at 3.99 and the Cash Ratio stands at 1.95. Considering the valuation of this stock, the price to sales ratio is 9.68.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Aug 11 ’25 when 10000.0 shares were sold. General Counsel, Smith Jason Drew completed a deal on Jul 28 ’25 to sell 7522.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 5149.0 shares on Jul 28 ’25.
